PCR: Prevalence, Cost, & Risk (6.27.2025)
Dr. Jack Cush reviews the news and journal reports from last week on RheumNow.com
Read Article
First FcRn inhibitor in #IIM: In #ALKIVIA, SC efgartigimod PH20 improved TIS vs placebo at 24wks (50.45 vs 35.65, p=0.0004), with faster time to TIS≥20 (30 vs 71.5d) & TIS≥40 (113d vs NE). More major responders too (TIS>60: 34% vs 9.5%).
#EULAR2025 #OP0002 https://t.co/ulxtL1NX2Y
Dr. John Cush @RheumNow( View Tweet )
FDA approves new drug for MAS in Still's disease. Gamifant (emapalumab-lzsg) is interferon gamma (IFNγ)–blocking Ab approved For HLH, now for use in adults & children w/ Still's Dz complicated by Macrophage Activation Syndrome. https://t.co/3div1fktWU https://t.co/VvSkuEoki5
Dr. John Cush @RheumNow( View Tweet )
Rheumatologists can’t ignore hypereosinopilic syndrome anymore, not when it borders on our diseases and therapies. Great takeaways on subtypes and therapies from Giacomo Emmi in an elegant talk #EULAR2025 @RheumNow https://t.co/yzQVt1fLKW https://t.co/kiX6kPPQP5
Links:
Dr. John Cush @RheumNow( View Tweet )
A Review of Intracranial GCA
A comprehensive review in Rheumatology on intracranial giant cell arteritis (icGCA) stresses that GCA is both an intracranial and extracranial large vessel vasculitis, with the former having unique presentations, and outcomes. https://t.co/NkN4gfcq3n
Dr. John Cush @RheumNow( View Tweet )
Full read overview of MDA-5 Dermatomyositis (DM) - pathogenesis, findings, & Rx. MDA-5 DM is a rare, aggressive amyopathic form with distinctive skin findings & rapidly progressive interstitial lung dz. Rx includes Hi dose steroids, calcineurin inhib & IV CTX (maybe JAKi, MMF)
Dr. John Cush @RheumNow( View Tweet )
A Review of Intracranial GCA
A comprehensive review in Rheumatology on intracranial giant cell arteritis (icGCA) stresses that GCA is both an intracranial and extracranial large vessel vasculitis, with the former having unique presentations, and outcomes.
A systematic review included 102
Social Determinants of Health in SLE
Dr. Mrinalini Dey interviews Dr. Elena Nikiphorou about the topic of social determinants of health in systemic lupus erythematosus, and data being presented at the EULAR 2025 meeting in Barcelona, Spain.
https://t.co/gSFIV8uIuE https://t.co/VpqzVRSwh9
Dr. John Cush @RheumNow( View Tweet )
The Value of Kidney Biopsy in Autoimmune Diseases
Dr. Andrea Fava shares his perspective from the EULAR 2025 meeting in Barcelona, Spain.
https://t.co/CA6Ak2scKb https://t.co/EK5wdpbzrl
Dr. John Cush @RheumNow( View Tweet )
Predictors and Outcomes in Systemic Sclerosis
The VEDOSS project has previously shown that 70% of patients with Raynaud’s phenomenon and at least one red flag – systemic sclerosis (SSc)-specific antibodies, puffy fingers, or an SSc pattern on nailfold capillaroscopy –will https://t.co/9dJn1qMQfy
Dr. John Cush @RheumNow( View Tweet )
Nailfold Capillaroscopy correlated w/ cardiac ECHO in Systemic Sclerosis. NFC & ECHOs studied in 30 SSc pts. Systolic & diastolic dysfunction most common in late SSc NFC patterns. Cardiac dysfunction seen w/ low capillary density, avascular areas, cap neoangiogenesis https://t.co/M6uU6i5cW4
Dr. John Cush @RheumNow( View Tweet )
The new (provisional) 2025 EULAR/ACR classification criteria for anti-synthetase syndrome
#EULAR2025 @RheumNow https://t.co/X6VjcN8XZe
Links:
David Liew @drdavidliew( View Tweet )
#EULAR2025 Abstr#OP0202 Phase 1/2 of Resel-cel, a 4-1BB-containing human CD19-CAR T cell (weight-based 1 x infusion) reported efficacy in 8 patients (#SLE and LN) at WK28. 2 x Grade 1 CRS & 1 x Grade 4 ICANS. 1 x HLH, not attributed to SLE flare. Need longterm data @RheumNow https://t.co/COCKlqw687
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
#WIN in systemic sclerosis (SSc):
-Ongoing trials now targeting multiple pathways.
-CONQUEST platform may reshape research in Ssc and other autoimmune diseases.
-Revised CRISS could replace single organ endpoints for approval.
#EULAR2025
@RheumNow https://t.co/kxSeFb5lAU
Links:
Adela Castro @AdelaCastro222( View Tweet )
What ‘CAR’ to drive?
#CAR-T buzz was at #EULAR2025
In multiple #rheumatic #diseases
#SLE
#Scleroderma
#Sjogrens
#myositis
Even #axial #SpA
Who - active, not a lot of damage
Which target 🎯
Which priming regiment
What will results be compared to?
Who will pay?
@RheumNow
Janet Pope @Janetbirdope( View Tweet )
#CAR-T in active #scleroderma #diffuse
open label
@sclerodermaUM presented improvement in
#nailfold #capillary patterns
Suggesting #vascular recovery
Hope is for lungs, skin and survival to improve but
These are ▶️
Early days ?risk
OP0338
#EULAR2025. @RheumNow @eular_org https://t.co/QhmO6gekXk
Janet Pope @Janetbirdope( View Tweet )
Despite the evolution of anti-synthetase antibodies, there’s a clear need for better ways to define the disease.
Enter the ACR/EULAR CLASS initiative - classification criteria for anti-synthetase syndrome
⬇️ see the next tweet
#EULAR2025 @RheumNow https://t.co/Z3rPOt1vlx
Links:
David Liew @drdavidliew( View Tweet )
EULAR/ACR Classification Criteria for #ASyS, the new acronym of Antisynthetase Syndrome
🔺️Do not apply if patient is positive for other antibodies like SSA
#EULAR2025
@RheumNow https://t.co/AD5tTipBtt
Nelly ZIADE 🍀 @Nellziade( View Tweet )
Joint pain and fatigue are actually the biggest issues for people living with haemochromatosis, but we in rheumatology don’t have organized care for them.
A call to action from Patrick Kiely, to do better by these patients
#EULAR2025 @RheumNow https://t.co/h3Zvov642L
David Liew @drdavidliew( View Tweet )
Manifestations of relapsing polychondritis
@Lupusreference @RheumNow #EULAR2025 https://t.co/EuPOdKKjax
Antoni Chan MD (Prof) @synovialjoints( View Tweet )
#Relapsing_Polychondritis
Main differential diagnosis is GPA
🔺️No ANCA and no renal involvement in relapsing polychondritis
@Lupusreference
#EULAR2025
@RheumNow https://t.co/QUJZ3EDjj3
Nelly ZIADE 🍀 @Nellziade( View Tweet )
FIBRONEER-ILD Ph3 PD4B inhibitor Nerandomilast
1100+ pts, 320+ w/ SARD-ILD wk52
FVC relative reduction of decline 9 mg bid 43% 18 mg bid 39% vs. PBO
HR 0.56 time to first acute exacerbation of ILD, hospitalisation for resp cause or death in higher dose group
11% https://t.co/CeXWB2GlOe
Aurelie Najm @AurelieRheumo( View Tweet )
Migrant health literacy challenges - Individual interviews with participants with rheumatic diseases (interpreters used)
multiple aspects -
Individual, Providers and system level
Navigating health care systems
#EULAR2025 @RheumNow https://t.co/cWQ6jP8RZe
Bella Mehta @bella_mehta( View Tweet )
Great talk by @Lupusreference on Relapsing Polychondritis and a highlight of #EULAR2025. Do not forget about the articular presentations of relapsing polychondritis @RheumNow https://t.co/1xZY7VkX1z
Antoni Chan MD (Prof) @synovialjoints( View Tweet )
"H Syndrome" review of 23 French pts. Autoinflammatory dz due to variants of SLC29A3 gene. Multisystem histiocytic lymphoproliferative disorder of young adults- skin 2/3, sensorineural hearing loss, fever w/ endo & autoimmune dz. Best responses w IL6 inhib. #EULAR2025 Abst https://t.co/F7NGI4TkJS
Dr. John Cush @RheumNow( View Tweet )
Recent Blogs
